Clinical trial
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
NCT00144378 · Charite University, Berlin, Germany, Other · Completed
Key facts
| NCT number | NCT00144378 |
|---|---|
| Title | Irinotecan Versus Only Best Supportive Care for Gastric Cancer |
| Official title | Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stomach Neoplasm, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Irinotecan |
| Enrollment | 44 |
| Start date | Oct 1, 2002 |
| First posted | Sep 5, 2005 |
| Last update posted | Apr 18, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: